RU2018147200A - SYSTEM FOR STABLE EXPRESSION OF TUMOR-ASSOCIATED ANTIGENS BASED ON LENTIVIRAL VECTOR - Google Patents

SYSTEM FOR STABLE EXPRESSION OF TUMOR-ASSOCIATED ANTIGENS BASED ON LENTIVIRAL VECTOR Download PDF

Info

Publication number
RU2018147200A
RU2018147200A RU2018147200A RU2018147200A RU2018147200A RU 2018147200 A RU2018147200 A RU 2018147200A RU 2018147200 A RU2018147200 A RU 2018147200A RU 2018147200 A RU2018147200 A RU 2018147200A RU 2018147200 A RU2018147200 A RU 2018147200A
Authority
RU
Russia
Prior art keywords
tumor
stable expression
associated antigens
sequence
seq
Prior art date
Application number
RU2018147200A
Other languages
Russian (ru)
Other versions
RU2018147200A3 (en
RU2725493C2 (en
Inventor
Елена Ивановна Фролова
Степан Петрович Чумаков
Юлия Евгеньевна Кравченко
Original Assignee
Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) filed Critical Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН)
Priority to RU2018147200A priority Critical patent/RU2725493C2/en
Publication of RU2018147200A3 publication Critical patent/RU2018147200A3/ru
Publication of RU2018147200A publication Critical patent/RU2018147200A/en
Application granted granted Critical
Publication of RU2725493C2 publication Critical patent/RU2725493C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (5)

1. Система на основе лентивирусной ДНК-конструкции для стабильной экспрессии опухоль-ассоциированных антигенов с последующим их транспортом в эндосому через систему комплекса МНС II, характеризующаяся тем, что она содержит нуклеотидную последовательность SEQ ID №4, кодирующую инвариантный домен комплекса МНС II CD74/Ii в качестве лидирующей сигнальной области, необходимой для транспорта белка в эндосому, присоединенную к нуклеотидной последовательности, кодирующей целевую полипептидную последовательность опухоль-ассоциированного антигена.1. A system based on a lentiviral DNA construct for stable expression of tumor-associated antigens and their subsequent transport to the endosome through the MHC II complex system, characterized in that it contains the nucleotide sequence of SEQ ID No. 4 encoding the invariant domain of the MHC II complex CD74 / Ii as the leading signal region necessary for transporting the protein to the endosome, attached to the nucleotide sequence encoding the target polypeptide sequence of the tumor-associated antigen. 2. Система на основе лентивирусной ДНК-конструкции по п. 1, характеризующаяся тем, что целевой полипептидной последовательностью опухоль-ассоциированного антигена является последовательность опухоль-ассоциированного антигена ERBB2/HER2.2. The system based on the lentiviral DNA construct according to claim 1, characterized in that the target polypeptide sequence of the tumor-associated antigen is a tumor-associated antigen sequence ERBB2 / HER2. 3. Система на основе лентивирусной ДНК-конструкции по п. 1 или 2, характеризующаяся тем, что для амплификации последовательности инвариантного домена комплекса МНС II CD74/Ii используют праймеры, выбранные из:3. The system based on the lentiviral DNA construct according to claim 1 or 2, characterized in that for the amplification of the sequence of the invariant domain of the complex MHC II CD74 / Ii use primers selected from: SEQ ID №6 AGAGAGGAATTCCATGCTGCGCATGAAGCSEQ ID No. 6 AGAGAGGAATTCCATGCTGCGCATGAAGC SEQ ID №7 AGAGAGTCTAGACTTGGGAGGCTTGGGAAGCTTCATGSEQ ID No. 7 AGAGAGTCTAGACTTGGGAGGCTTGGGAAGCTTCATG
RU2018147200A 2018-12-28 2018-12-28 System for stable expression of tumor-associated antigens based on lentiviral vector RU2725493C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2018147200A RU2725493C2 (en) 2018-12-28 2018-12-28 System for stable expression of tumor-associated antigens based on lentiviral vector

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018147200A RU2725493C2 (en) 2018-12-28 2018-12-28 System for stable expression of tumor-associated antigens based on lentiviral vector

Publications (3)

Publication Number Publication Date
RU2018147200A3 RU2018147200A3 (en) 2020-06-30
RU2018147200A true RU2018147200A (en) 2020-06-30
RU2725493C2 RU2725493C2 (en) 2020-07-02

Family

ID=71509391

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018147200A RU2725493C2 (en) 2018-12-28 2018-12-28 System for stable expression of tumor-associated antigens based on lentiviral vector

Country Status (1)

Country Link
RU (1) RU2725493C2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US20100278904A1 (en) * 2005-11-30 2010-11-04 Copenhagen University Nucleotide vaccine
WO2010057501A1 (en) * 2008-11-21 2010-05-27 Københavns Universitet (University Of Copenhagen) Priming of an immune response
RU2507265C2 (en) * 2012-05-12 2014-02-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической иммунологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКИ" СО РАМН) RECOMBINANT PLASMID DNA pCI-UB-POLYEPI CONTAINING EPITOPES OF TUMOUR-ASSOCIATED ANTIGENS FOR COLORECTAL CANCER AND METHOD OF ITS APPLICATION FOR STIMULATION OF SPECIFIC ANTITUMOUR IMMUNE RESPONSE AGAINST COLORECTAL CANCER CELLS

Also Published As

Publication number Publication date
RU2018147200A3 (en) 2020-06-30
RU2725493C2 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
Faulkner et al. Reduced antibody cross-reactivity following infection with B. 1.1. 7 than with parental SARS-CoV-2 strains
JP2015096070A5 (en)
MY198621A (en) T cell receptors
JP2020529841A5 (en)
UA124343C2 (en) Adeno-associated virus variant capsids and methods of use thereof
JP2017518037A5 (en)
JP2018529380A5 (en)
MX2019003462A (en) A universal platform for car therapy targeting a novel antigenic signature of cancer.
JP2020517635A5 (en)
JP2018514208A5 (en)
JP2019506841A5 (en)
IL275497B (en) Serum albumin-binding fibronectin type iii domains
AU2015205530A8 (en) Multi-specific polypeptide useful for localized tumor immunomodulation
PH12018502293A1 (en) Humanized anti-basigin antibodies and the use thereof
JP2018514209A5 (en)
MY192642A (en) Novel tilapia virus and uses thereof
JP2018531624A5 (en)
MX2017005642A (en) Anti-ang2 antibodies and methods of use.
MX2018015629A (en) Dual overlapping adeno-associated viral vector system for expressing abc4a.
Hadifar et al. Multimeric recombinant M2e protein-based ELISA: a significant improvement in differentiating avian influenza infected chickens from vaccinated ones
MX2019002178A (en) Fusion peptides with antigens linked to short fragments of invariant chain (cd74).
Wendlandt et al. Complete sequence of the multi-resistance plasmid pV7037 from a porcine methicillin-resistant Staphylococcus aureus
Malysheva et al. The genus Tremella (Tremellales, Basidiomycota) in Russia with description of two new species and proposal of one nomenclatural combination
WO2018069947A8 (en) Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
RU2018147200A (en) SYSTEM FOR STABLE EXPRESSION OF TUMOR-ASSOCIATED ANTIGENS BASED ON LENTIVIRAL VECTOR

Legal Events

Date Code Title Description
QB4A Licence on use of patent

Free format text: LICENCE FORMERLY AGREED ON 20210628

Effective date: 20210628